Continuing litigation that began in 2012, Illumina alleges that Qiagen's GeneReader infringes on a patent it holds related to sequencing-by-synthesis technology.
The parties involved in the CRISPR patent fight recently held a conference call, Stat News reports.
A patent examiner has issued an Initial Interference Memo in the CRISPR patent fight, possibly leading to an interference proceeding, according to the Law and Biosciences Blog.
The report, which takes a look at patent issues as it relates to confirmatory genetic tests, acknowledged that federal legislation has dramatically changed the landscape in recent years.
Researchers report in PLOS One on their examination of the percentage of women represented on patent filings.
Title: Methods and Means for Producing Efficient Silencing Construct Using Recombinatorial Cloning
Patent Number: 8,877,435
Title: Construction of Protein-responsive shRNA/RNAi Control System Using RNP Motif
Patent Number: 8,871,437
NEW YORK (GenomeWeb) – The US Patent and Trademark Office appeals board has invalidated certain claims on a patent held by Illumina that is the subject of an infringement lawsuit by the company against Qiagen's Intelligent Bio-Systems.
Title: RNA Interference-mediating Small RNA Molecules
Patent Number: 8,853,384
Filed: Dec. 2, 2009
Title: Treatment of Cancer by Inhibition of IGFBPs and Clusterin
Patent Number: 8,835,401
Filed: May 29, 2013
In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.
The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.
Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.
In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.